Observational Disease Registry of Patients Treated with Systemic Mold-Active Triazoles

C
Chadi Hage, MD

Primary Investigator

Overview

This study seeks to describe representative real-world patterns of care for the management of invasive fungal infections (IFIs) ,including invasive mold infection (IMI). Specifically, the study goals are to examine real world patient characteristics and treatment patterns, associated healthcare resource utilization, and outcomes associated with use of mold-active triazoles (MATs) to treat IFIs.

Description

This study seeks to describe representative real-world patterns of care for the management of invasive fungal infections (IFIs) ,including invasive mold infection (IMI). Specifically, the study goals are to examine real world patient characteristics and treatment patterns, associated healthcare resource utilization, and outcomes associated with use of mold-active triazoles (MATs) to treat IFIs.

Eligibility

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Invasive fungal infection,Invasive mold infection,Mold-Active Triazoles
  • Age: Between 18 Years - 100 Years
  • Gender: All

Inclusion Criteria
Initiating one of the following target drugs: ISAV, VORI, POSA. Patients may be enrolled within 60 days from the time of treatment initiation
Exclusion Criteria
Currently enrolled in any clinical trial with an investigational antifungal agent. Individuals who subsequently enroll in an investigational antifungal study will be discontinued and data collected up to the time of investigational product will be evaluable.
Retrospective patients who died before entering the study.
Patients who previously participated in this registry.
Additional Information:
Participants will not be paid for their participation.

Updated on 19 Dec 2022. Study ID: 1608845528

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center